Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vibe GrowthVIBEF 48 Debt-to-EBITDA is 2.68 as of Mar. 2026. GuruFocus rates VIBEF with a GF Score™ of 48/100 and a GF Value™ of $1.31 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 689 Drug Manufacturers companies, Vibe Growth ranks worse than 78.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Vibe Growth's Debt-to-EBITDA or its related term are showing as below:
VIBEF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.55 Med: -0.21 Max: 4.52
Current: 4.52
During the past 13 years, the highest Debt-to-EBITDA Ratio of Vibe Growth was 4.52. The lowest was -2.55. And the median was -0.21.
VIBEF's Debt-to-EBITDA is ranked worse than 78.96% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs VIBEF: 4.52
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Vibe Growth Debt-to-EBITDA Related Terms
Vibe Growth Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Vibe Growth's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vibe Growth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vibe Growth Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vibe Growth's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vibe Growth's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Vibe Growth (VIBEF) has a Debt-to-EBITDA of 2.68 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vibe Growth. According to the industry distribution chart, Vibe Growth ranks #544 out of 689 companies in the Drug Manufacturers industry, placing it in the top 79%.
Is Vibe Growth's Debt-to-EBITDA too high?
Vibe Growth's current Debt-to-EBITDA is 2.68. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Vibe Growth's value of 2.68 is 63.4% above this industry median. Based on the distribution chart, Vibe Growth ranks #544 out of 689 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vibe Growth has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vibe Growth's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vibe Growth ranks #544 out of 689 companies for Debt-to-EBITDA. This places Vibe Growth in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Vibe Growth's value of 2.68 is 63.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vibe Growth's current Debt-to-EBITDA of 2.68 is 63.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vibe Growth. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vibe Growth's current Debt-to-EBITDA is 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vibe Growth stock overvalued right now?
Based on GuruFocus' analysis, Vibe Growth (VIBEF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.31, compared to a current price of $0.39 — trading 70.2% below its estimated fair value. The current Debt-to-EBITDA is 2.68 and 63.4% above the Drug Manufacturers industry median of 1.64. Vibe Growth's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Vibe Growth (VIBEF), the current Debt-to-EBITDA is 2.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vibe Growth (VIBEF) Overvalued in 2026?
Based on GuruFocus' analysis, Vibe Growth stock appears to be undervalued.
The current stock price of $0.39 is trading 70.2% below its estimated GF Value™ of $1.31.
GuruFocus considers Vibe Growth to be Possible Value Trap.
Key valuation signals for VIBEF:
Debt-to-EBITDA: 2.68
GF Value™: $1.31 vs. price of $0.39 (70.2% below fair value)
Industry Position: 63.4% above the Drug Manufacturers median (#544 of 689)
No single metric tells the full story. See the VIBEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vibe Growth Corp is engaged in the evaluation, acquisition, and development of cannabis cultivation, distribution, and manufacturing assets and retail cannabis dispensaries, predominantly in the U.S., to become a vertically integrated cannabis operator. The company currently operates four dispensaries, one distribution, and one cultivation operation in the State of California, plus one dispensary in Portland, Oregon. It offers cannabis infused products across various categories such as vaporizers, concentrates, edibles, topicals, pre-rolls, etc., and through different brands including Alien Labs, Almora Farm, Buddies, Chill Bud, Highatus, and Others.
48GF Score
Get the complete analysis for VIBEF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIBEF has been successfully added to your 
